Yingkang Life reported stronger first-half 2026 results, with revenue rising 20.56% year on year to 1.02 billion yuan ($150.7 million) and net profit attributable to shareholders increasing 9.01% to 67.4 million yuan ($10.0 million). Net profit excluding non-recurring items grew 5.22% to 63.75 million yuan ($9.5 million), while net cash flow from operating activities climbed 92.21% to 286 million yuan ($42.4 million). Medical services were the main growth driver, generating 822 million yuan ($121.9 million) of revenue, up 25.86%, as self-operated hospitals served 327,700 patients, with outpatient visits up 14.99%, inpatient admissions up 22.76% and surgical volume up 93.11%. Grade III and IV procedures rose 108.82%, pointing to a shift toward higher-complexity specialty care. The medical devices segment remained comparatively steady, with revenue up 2.34%. The cash flow improvement was also supported by Changsha Kexin's recovery of 78.51 million yuan ($11.6 million) in other receivables from former shareholders, which the company said was a non-recurring factor. Yingkang Life said artificial intelligence is central to its strategy as it invests in oncology, senior care and clinical innovation and shifts from scale expansion toward specialty capability, treatment mix optimization and full-cycle patient value creation.